U.S. Basic Materials Stock News

NYSE:BTU
NYSE:BTUOil and Gas

Should Federal Backing for Rare Earths Shift Peabody Energy’s (BTU) Coal‑Centric Investment Narrative?

Earlier this month, Peabody Energy announced that the U.S. Department of Energy selected it for funding to advance rare earth element and critical mineral production from its extensive Powder River Basin resource base in Wyoming. This support, alongside a Wyoming Energy Authority grant, highlights Peabody’s effort to leverage its coal-mining scale and infrastructure to help build a more secure domestic supply of materials important for U.S. energy, technology and national security...
NYSE:WELL
NYSE:WELLHealth Care REITs

Welltower Stock And 2 U.S. REITs For Lower Rate Expectations

Cooling inflation, a less urgent Federal Reserve, and easing gasoline prices are reshaping expectations for interest rates, and that can matter a lot for U.S. Real Estate Investment Trusts. Lower inflation pressures may reduce the risk of rapid rate hikes, which often influences how investors think about income focused stocks, funding costs, and real estate valuations. This article looks at three REIT stocks from a focused screener that appear more directly exposed to these shifting inflation...
NYSE:LYB
NYSE:LYBChemicals

Did Mondelez’s Recycled Marabou Wrapper Just Shift LyondellBasell’s (LYB) Circular Plastics Narrative?

In July 2026, LyondellBasell announced that Mondelez International is using new Marabou chocolate bar packaging made with LyondellBasell CirculenRevive polymers, incorporating 75% recycled content via an ISCC PLUS-certified mass balance approach in partnership with Amcor, Taghleef Industries and others. This collaboration converts hard-to-recycle mixed plastic waste into food-grade flexible packaging, aligning with tightening European recycling rules and positioning LyondellBasell as a key...
NasdaqCM:MNSB
NasdaqCM:MNSBBanks

MainStreet Bancshares (MNSB) Stock Faces Loan Quality Questions As 2.9% NPLs Shape Q2 View

MainStreet Bancshares (MNSB) has reported Q2 2026 results with total revenue of US$18.5 million and basic EPS of US$0.58, alongside quarterly net income of US$4.1 million, as the company continues to build on its recent return to profitability over the last 12 months. The company has seen quarterly revenue move from US$17.4 million in Q1 2025 to US$18.5 million in Q2 2026, while basic EPS has shifted from US$0.25 to US$0.58 over the same span. Investors may now focus on how durable these...
NasdaqGS:GEHC
NasdaqGS:GEHCMedical Equipment

GE HealthCare Technologies (GEHC) Following Catholic Health Deal Looks Like A Buying Opportunity

GE HealthCare Technologies (GEHC) has drawn fresh attention after Catholic Health agreed to a 10 year, approximately $500 million Care Alliance that focuses on advanced imaging, AI enabled tools, and system wide technology modernization. See our latest analysis for GE HealthCare Technologies. Despite a series of new partnerships and product announcements, including the Catholic Health Care Alliance and the Mayo Clinic MI-BET collaboration, GE HealthCare Technologies’ share price return has...
NYSE:NOW
NYSE:NOWSoftware

ServiceNow (NOW) Expands AI Partnerships As Fair Value Debate Heats Up

ServiceNow (NOW) has rolled out a cluster of AI focused integrations with Ciroos, Esri, Hexnode, and Hitachi Digital Services, just as investors prepare for the company’s upcoming second quarter earnings update. See our latest analysis for ServiceNow. Despite this run of AI partnerships, ServiceNow’s share price has had a mixed year, with a 30 day share price return of 10.16% and a year to date share price return down 28.99%, while the 1 year total shareholder return is down 45.46%. This...
NasdaqGM:ANIP
NasdaqGM:ANIPPharmaceuticals

ANI Pharmaceuticals (ANIP) On Strong ILUVIEN Trial Data Is The Stock A Bargain

ANI Pharmaceuticals (ANIP) recently reported statistically significant Phase 4 SYNCHRONICITY trial results for its fluocinolone acetonide intravitreal implant, ILUVIEN, in chronic non-infectious posterior segment uveitis, including measurable gains in visual acuity and retinal thickness outcomes. See our latest analysis for ANI Pharmaceuticals. At a share price of US$77.72, ANI Pharmaceuticals has seen mild share price pressure recently, with the 7 day share price return down 4.14%. The 1...
NasdaqGS:MRVL
NasdaqGS:MRVLSemiconductor

Marvell Technology (MRVL) Rebounds With AI Optimism While Valuation Questions Linger

Marvell Technology (MRVL) moved higher as semiconductor stocks rebounded, with investors responding to improving sentiment around artificial intelligence spending and looking ahead to a packed stretch of technology earnings after recent sector volatility. See our latest analysis for Marvell Technology. At a share price of US$194.94, Marvell Technology has seen short term momentum cool, with a 1 month share price return down 37.23% and a 7 day share price return down 10.38%. However, the 1...
NYSE:BRK.A
NYSE:BRK.ADiversified Financial

Berkshire Hathaway (BRK.A) Could Be 22% Undervalued After Buffett’s 2034 Donation Plan

Buffett’s $140 billion exit plan reshapes Berkshire’s ownership picture Warren Buffett’s decision to donate his entire roughly $140 billion Berkshire Hathaway (BRK.A) stake by 2034, including recent large Class A to Class B conversions, is reshaping the company’s long term ownership profile for investors. See our latest analysis for Berkshire Hathaway. Against the backdrop of Buffett’s planned share donations and Berkshire Hathaway’s growing focus on concentrated holdings such as Apple and...
NYSE:DK
NYSE:DKOil and Gas

Is Delek US (DK) Reframing Its Profit Story Through the Enterprise Optimization Plan’s Early Wins?

In recent days, Delek US Holdings’ Enterprise Optimization Plan has begun to show clearer operational benefits, prompting analysts to lift earnings estimates and reflect stronger confidence in the company’s profitability outlook. This shift highlights how concrete cash-flow improvement targets and visible execution progress can materially reshape perceptions of a refiner’s longer-term earnings power and business mix. We will now explore how the early success of Delek’s Enterprise...
NasdaqGS:LIVN
NasdaqGS:LIVNMedical Equipment

LivaNova (LIVN) And The Narrative Behind Its Undervalued View

LivaNova (LIVN) has drawn investor attention after a recent move in the stock, with returns over the past 3 months and year contrasting with softer daily and weekly performance. See our latest analysis for LivaNova. The recent pullback, with a 1-day share price return of 1.85% and a 7-day share price return of 4.54%, sits against stronger momentum. This includes a 90-day share price return of 22.75% and a 1-year total shareholder return of 87.04%, indicating that longer term gains have been...
NasdaqGS:OZK
NasdaqGS:OZKBanks

Bank OZK (OZK) Expands Equipment Finance Reach, Is The Stock Fairly Valued?

Empire Asset Finance has closed its first institutional warehouse credit facility with Bank OZK (OZK), highlighting the bank’s push into equipment financing and potential implications for its lending mix to middle-market clients. See our latest analysis for Bank OZK. At a share price of $51.43, Bank OZK has seen its momentum build recently, with a 30 day share price return of 4.41% and a year to date share price return of 9.33%. Its 5 year total shareholder return of 48.86% reflects a longer...
NasdaqGS:LFST
NasdaqGS:LFSTHealthcare

How LifeStance’s Board and Committee Shake-Up Will Impact LifeStance Health Group (LFST) Investors

On July 2, 2026, LifeStance Health Group announced that director Jeffrey Rhodes resigned from the board and its committees, while three new directors, Thurman Justice, Lori Goltermann, and Safwan Shabab, were appointed with defined terms and committee roles. The addition of three directors with specific responsibilities across audit, quality and compliance, compensation, and governance committees signals a meaningful refresh of LifeStance’s oversight structure and potential shifts in...
NYSE:COHR
NYSE:COHRElectronic

Is Coherent (COHR) Undervalued As AI Infrastructure Optimism Lifts The Stock?

Coherent (COHR) stock moved higher as semiconductor and AI infrastructure companies attracted renewed interest, even while escalating U.S. Iran tensions pressured major indices and prompted investors to reassess how this tech supplier fits into evolving AI demand. See our latest analysis for Coherent. Coherent’s recent 2.81% 1 day share price gain to US$285.40 comes after a sharp 26.74% share price decline over the past 30 days. Its very large 3 year total shareholder return suggests longer...
NYSE:BX
NYSE:BXCapital Markets

Blackstone (BX) Could Be 14% Undervalued On Its Ode AI Push

Blackstone (BX) is back in focus after helping launch Ode with Anthropic, an AI services company backed by a global investor consortium. This has raised fresh questions about how its growing AI exposure might influence the stock. See our latest analysis for Blackstone. Recent moves into AI services sit against a weaker share price backdrop, with Blackstone’s share price down 22.16% year to date and its 1 year total shareholder return down 23.15%. However, the 3 year total shareholder return...
NasdaqGM:HROW
NasdaqGM:HROWPharmaceuticals

Can New Retina Data Deepen Harrow’s (HROW) Moat In Ophthalmology Or Just Refine Its Story?

Harrow recently highlighted three new clinical and real-world studies for its retina portfolio at the 2026 ASRS Annual Meeting, including interim randomized data and a nearly 20,000‑injection safety analysis for IHEEZO, plus interim post‑marketing findings for BYOOVIZ from Samsung Bioepis. The early signals of improved post‑injection patient experience with IHEEZO, alongside large‑scale safety data and expanding evidence for BYOOVIZ, strengthen the clinical underpinnings of Harrow’s retina...
NasdaqGS:ZION
NasdaqGS:ZIONBanks

How Investors May Respond To Zions (ZION) Q2 Results And New Leadership In Idaho Corporate Banking

Zions Bancorporation National Association recently reported its second-quarter earnings, following earlier expectations for higher year-on-year earnings per share and steady revenue growth. Alongside these earnings, the recent additions of Daniel J. Ryan to the board and Flip Kleffner to lead Idaho corporate banking highlight governance and regional commercial banking focus that could influence how investors view Zions’ longer-term positioning. We’ll now examine how the anticipated earnings...
NYSE:DTE
NYSE:DTEIntegrated Utilities

DTE Energy (DTE) Pulls Back On Grid Growth Story, Is The Stock Still Cheap?

DTE Energy (DTE) stock is back in focus after recent trading pressure, with the share price down 1.5% over the past day and 3.1% over the past week, prompting fresh interest in its fundamentals. See our latest analysis for DTE Energy. Stepping back from the recent pullback, DTE Energy’s 11.96% year to date share price return and 9.37% 1 year total shareholder return point to momentum that has cooled slightly in the very short term as investors reassess risk and income prospects around the...
NasdaqGS:VRTX
NasdaqGS:VRTXBiotechs

Vertex Pharmaceuticals (VRTX) Stock Trades Below Fair Value After Deal Plans

Vertex Pharmaceuticals stock has delivered a 141.5% return over the past 5 years, and the latest intrinsic value work using a Discounted Cash Flow (DCF) approach now points to the shares trading at a discount to that estimate, even as the broader valuation checks look more mixed. With the market pricing in both the planned Crinetics Pharmaceuticals acquisition and ongoing revenue from existing partnerships, investors are weighing whether the current price still leaves enough cushion. A...
NasdaqGM:IRMD
NasdaqGM:IRMDMedical Equipment

IRADIMED (IRMD) As MRI Pump Upgrade Narrative Points To Fair Value Above The Stock

IRADIMED stock snapshot after recent performance IRADIMED (IRMD) has drawn fresh attention after a period of steady trading, with the stock flat over the past day while showing gains over the past month and past 3 months. See our latest analysis for IRADIMED. At a share price of $97.03, IRADIMED has seen a 30 day share price return of 5.24% and a 1 year total shareholder return of 75.09%. This suggests recent momentum has built on already strong longer term gains. If IRADIMED's move has...
NYSE:DFIN
NYSE:DFINCapital Markets

Donnelley Financial Solutions (DFIN) Rebounds In Focus, Is The Stock Still Cheap?

Donnelley Financial Solutions (DFIN) has drawn fresh attention after recent trading left the stock with a mixed return profile, including a gain over the past month but a decline across the past 3 months. See our latest analysis for Donnelley Financial Solutions. The 1-month share price return of 25.27% for Donnelley Financial Solutions contrasts with a 1-year total shareholder return that is down 19.92%. This suggests that recent momentum has picked up following a weaker period. If you want...
NasdaqGS:HON
NasdaqGS:HONIndustrials

Honeywell International (HON) Could Be 29% Below Fair Value After Lowered Earnings Expectations

Honeywell International (HON) has reaffirmed its 2026 sales outlook and detailed earnings guidance that separates the impact of its Aerospace Technologies spin off, putting the stock’s post breakup profit profile under closer investor review. See our latest analysis for Honeywell International. Despite reaffirmed 2026 guidance and the Aerospace Technologies spin off, Honeywell International’s recent share price performance has been weak, with the 30 day share price return declining 50.62% and...
NasdaqGS:COST
NasdaqGS:COSTConsumer Retailing

Costco Wholesale (COST) Could Be 14% Undervalued Following Fresh Product Launches

Costco Wholesale (COST) has come back into focus after a cluster of partner announcements, with Laifen, Jackery and Tick Solutions all choosing the membership retailer for new or exclusive product launches across U.S. warehouses and Costco.com. See our latest analysis for Costco Wholesale. Despite the fresh product partnerships and steady operational news, Costco Wholesale’s recent 90 day share price return is down 6.96%, while the year to date share price return is 9.51% and the 5 year total...
NYSE:LLY
NYSE:LLYPharmaceuticals

The Bull Case For Eli Lilly (LLY) Could Change Following Its Deeper Role In Illumina’s Billion Cell Atlas

In January 2026, Illumina announced the launch of its Billion Cell Atlas alliance, naming Eli Lilly as a founding member in a program that uses CRISPR-based, large-scale genomic perturbation data and AI to map disease biology across more than 200 cell lines and hundreds of cell types. By mid-July 2026, the Atlas had already sequenced over 350 million cells and generated several petabytes of data, positioning Lilly closer to the core of AI-driven target discovery and mechanistic insights for...